News | February 16, 2022
Clean Science and Technology to invest Rs. 300 - 500 Cr on expansion
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
The recommendation has been sent to the DCGI for approval
Launches a host of innovative products & solutions across the entire flexible packaging value chain in October - December 2021
Expected to open later this year, the facility will significantly increase distribution capacity to meet the growing demand for production materials by Ireland's biopharma industry
The three prequalified products are manufactured by the originator company, Roche, but the listings should pave the way for more companies coming forward to seek WHO prequalification
Monitoring results demonstrated a good safety profile of the combination. No serious adverse events related to vaccination were registered
Key takeaways of recent quarter & conference call highlights
Adds five years of market exclusivity on approval
On track to complete the BLA submission in the first half of 2022
Subscribe To Our Newsletter & Stay Updated
